We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

TME Pharma NV (ALTME) EUR1

Sell:€0.24 Buy:€0.24 Change: €0.0035 (1.41%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:€0.24
Buy:€0.24
Change: €0.0035 (1.41%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:€0.24
Buy:€0.24
Change: €0.0035 (1.41%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

TME Pharma NV formerly NOXXON Pharma NV is a biotechnology company focusing on developing therapies for the treatment of cancers. The Company specializes in approaches targeting the tumor microenvironment (TME) in which cancer cells exist. Its technology breaks tumor protection barriers against the immune system and blocks tumor repair by neutralizing chemokines in the TME. TME Pharma’s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. their clinical programs in glioblastoma and pancreatic cancer have delivered results and further development is planned.

Contact details

Address:
Max-Dohrn-Str. 8-10
BERLIN
10589
Germany
Telephone:
+49 (30) 7262470
Website:
https://www.tmepharma.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ALTME
ISIN:
NL0015000YE1
Market cap:
€7.07 million
Shares in issue:
5.30 million
Sector:
Biotechnology
Exchange:
Euronext Paris
Country:
Netherlands
Currency:
Euro
Indices:
n/a

Key personnel

  • Maurizio PetitBon
    Chairman of the Supervisory Board
  • Aram Mangasarian
    Chief Executive Officer, Member of the Management Board
  • Martine Van Vugt
    Independent Deputy Chairperson of Supervisory Board
  • Bryan Jennings
    Chief Financial Officer, Member of the Management Board
  • Jarl Jungnelius
    Senior Medical Advisor, Member of the Management Board

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.